BCAX — Bicara Therapeutics Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$23.23
-$0.19 (-0.79%)
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ. It is led by Claire Mazumdar Clemon M.B.A., Ph.D., based in 116 Huntington Avenue, Boston, MA, United States, 02116, with about 103 employees. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Net income was -$36.3M. BCAX currently screens at market cap $1.51B.
Use this BCAX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCAX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCAX SEC filings page. Lician reads the product cache first so this HTML stays unique to Bicara Therapeutics Inc. Common Stock even when a live quote feed is slow.
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
BCAX Key Statistics
Market Cap
$1.51B
Volume
409,256
Previous Close
$23.58
Day Range
$23.91 – $24.94
P/B Ratio
2.93
EPS
-$4.05
Revenue
$0.00
Net Income
-$68.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
103
BCAX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$68.00M | -$51.98M |
| EPS (Diluted) | -$4.05 | -$89.61 |
Total Assets
$510.00M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$489.71M
Operating Cash Flow
-$74.75M
Free Cash Flow
$0.00
Bicara Therapeutics Inc. Common Stock Company Information
- CEO & Director
- Claire Mazumdar Clemon M.B.A., Ph.D.
- Headquarters
- 116 Huntington Avenue, Boston, MA, United States, 02116
- Website
- www.bicara.com
- Phone
- 617 468 4219
- IPO / Founded
- 2024-09-13
- Sector
- Healthcare
- Industry
- Biotechnology